S100A11 and neoplasm: To the best of our knowledge, this is the first report describing that S100A11-specific targeting potentially presents dual therapeutic benefits by not only controlling tumour progression but also sensitising a chemotherapeutic cytotoxic response (Schematic illustration in Additional file 3: Figure S3).